本論文以吲哚(indole)為核心之微管蛋白聚合抑制劑進行比較分子場分析法(CoMFA)之三維定量構效關係(3S-QSAR)研究。以細胞實驗所得IC50作為活性資料，以Gold進行docking計算取得化合物構形。將42個化合物作為training set計算，得到交叉驗證相關度(q2)為0.62，以此模型預測包含17個化合物之test set，得到預測相關度(r2)為0.71，足以證明此模型深具可信度。此計算模型可以提供三度空間資訊(見下圖)，R3取代位置適合立體阻礙較大取代基；R1、R2與R4位置不適合立體阻礙大之取代基；R5與R6取代位置，部份空間呈現適合立體阻礙大取代基，部分空間則否。關於電荷作用力，R3取代位置適合偏負電荷取代基，R2取代位置有部份空間適合偏負電荷取代基，而部份空間適合偏正電荷取代基，R5取代位置適合偏正電荷，R4取代位置適合偏負電荷，R1與R6無明顯適合電性。關於模型與生物活性(IC50)被討論與分析。依據模型設計兩化合物，預測生物活性(IC50)最高提高10倍。此結果有助於發展以微管蛋白為目標之抗有絲分裂藥物。

A 3D-QSAR study of anti-tubulin agents with indole as nucleus core using the comparative molecular field analysis (CoMFA) was carried out. The structures of the compounds were obtained using docking calculation. CoMFA calculations for examined 42 ligands as the training set gave q2 value of 0.6 in correlation with IC50 values. Calculation for the test set of 18 ligands results in an r2 value of 0.7. The calculated results suggest that the R3 functional group site (see the below figure) favors bulky groups while R1, R2, and R4 disfavor. At the R5 and R6 sites, parts of the region favor bulky groups while other region disfavors. In the electrostatic aspect, the R3 site was found to favor groups with negative partial charges. At the R2 site, part of region favors groups with negative partial charges while other region favors groups with positive partial charges. At the R4 and R5 sites, they favor groups with negative and positive partial charges, respectively, with less favor magnitude compared with R2 and R3 sites. The R1 and R6 sites do not exhibit significant electrostatic favor. Correlation of the results with IC50 values of ligands were analyzed and discussed. These results should be of aid in developing better anti-tubulin agents of this kind.

[1] M. Congreve, C. W. Murray, T. L. Blundell, Drug Discovery Today 2005, 10, 895.
[2] P. S. Charifson, I. D. Kuntz, in Practical Application of Computer-Aided Drug Design (Ed.: P. S. Charifson), 1997, p. 1.
[3] H. Kubinyi, 3D QSAR in Drug Design, 1998.
[4] J. W. Essex, Journal of Computer-Aided Molecular Design, 2002, 16, 151.
[5] J. Bajorath, Nature Reviews Drug Discovery 2004, 3, 935.
[6] R. D. Cramer, III, D. E. Patterson, J. D. Bunce, Journal of the American Chemical Society 1988, 110, 5959.
[7] M. A. Jordan, L. Wilson, Nature Review Cancer 2004, 4, 253.
[8] A. Krebs, K. N. Goldie, A. Hoenger, European Molecular Biology Organization Reports 2005, 6, 227.
[9] K. M. R. Bhat, V. Setaluri, Clinical Cancer Research 2007, 13, 2849.
[10] J. R. Jackson, D. R. Patrick, M. M. Dar, P. S. Huang, Nature Review Cancer 2007, 7, 107.
[11] B. Gigant, C. Wang, R. B. G. Ravelli, F. Roussi, M. O. Steinmetz, P. A. Curmi, A. Sobel, M. Knossow, Nature 2005, 435, 519.
[12] R. B. G. Ravelli, B. Gigant, P. A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Nature 2004, 428, 198.
[13] J. Kelling, K. Sullivan, L. Wilson, M. A. Jordan, Cancer Research 2003, 63, 2794.
[14] G. M. Tozer, C. Kanthou, C. S. Parkins, S. A. Hill, International journal of experimental pathology 2002, 83, 21.
[15] G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A. A. Genazzani, Journal of Medicinal Chemistry 2006, 49, 3033.
[16] D. W. Siemann, D. J. Chaplin, M. R. Horsman, Cancer 2004, 100, 2491.
[17] C. Kanthou, G. M. Tozer, Blood 2002, 99, 2060.
[18] G. M. Tozer, V. E. Prise, J. Wilson, M. Cemazar, S. Shan, M. W. Dewhirst, P. R. Barber, B. Vojnovic, D. J. Chaplin, Cancer Research 2001, 61, 6413.
[19] J. P. Liou, Y. L. Chang, F. M. Kuo, C. W. Chang, H. Y. Tseng, C. C. Wang, Y. N. Yang, J. Y. Chang, S. J. Lee, H. P. Hsieh, Journal of Medicinal Chemistry 2004, 47, 4247.
[20] N. Mahindroo, J.-P. Liou, J.-Y. Chang, H.-P. Hsieh, Expert Opinion on Therapeutic Patents 2006, 16, 647.
[21] Y.-W. Chang, W.-C. Chen, K.-T. Lin, L. Chang, H.-T. Yao, H.-P. Hsieh, S.-J. Lan, C.-T. Chen, Y.-S. Chao, T.-K. Yeh, Journal of Chromatography B 2007, 846, 162.
[22] J.-P. Liou, N. Mahindroo, C.-W. Chang, F.-M. Guo, S. W.-H. Lee, U.-K. Tan, T.-K. Yeh, C.-C. Kuo, Y.-W. Chang, P.-H. Lu, Y.-S. Tung, K.-T. Lin, J.-Y. Chang, H.-P. Hsieh, ChemMedChem 2006, 1, 1106.
[23] A. Crum-Brown, T. Frazer, Transactions of the Royal Society of Edinburgh 1868-1869, 25, 257.
[24] C. Hansch, Accounts of Chemical Research 1969, 2, 232.
[25] Z. Simon, I. Badileuscu, T. Racovitan, Journal of Theoretical Biology 1977, 66, 485.
[26] Z. Simon, N. Dragomir, M. G. Plauchithiu, S. Holban, H. Glatt, F. Kerek, European Journal of Medicinal Chemistry 1980, 15, 521.
[27] G. Jones, P. Willett, R. C. Glen, A. R. Leach, R. Taylor, Journal of Molecular Biology 1997, 267, 727.
[28] P. Wolohan, D. E. Reichert, Journal of Computer-Aided Molecular Design, 2004, 17, 313.
[29] X. Pan, N. Tan, G. Zeng, H. Han, H. Huang, Bioorganic & Medicinal Chemistry 2006, 14, 2771.
[30] H. Liu, X. Huang, J. Shen, X. Luo, M. Li, B. Xiong, G. Chen, J. Shen, Y. Yang, H. Jiang, K. Chen, Journal of Medicinal Chemistry 2002, 45, 4816.
[31] F. Cheng, J. Shen, X. Luo, W. Zhu, J. Gu, R. Ji, H. Jiang, K. Chen, Bioorganic & Medicinal Chemistry 2002, 10, 2883.
[32] J. Du, J. Qin, H. Liu, X. Yao, Journal of Molecular Graphics and Modelling 2008, In Press, Corrected Proof.
[33] P. A. Datar, E. C. Coutinho, Journal of Molecular Graphics and Modelling 2004, 23, 239.
[34] M. J. D. Powell, Mathematical Programming 1977, 12, 241.
[35] M. R. Hestenes, E. Stiefel, Journal of Research of the National Bureau of Standards 1952, 49, 409.
[36] K. Pearson, Philosophical Magazine 1901, 2, 559.
[37] W. Lindberg, J.-A. Persson, S. Wold, Analytical Chemistry 1983, 55, 643.
[38] A. R. Leach, in Molecular Modelling, principles and applications., 2nd ed., Prentice Hall, 2001, p. 701.
[39] S. J. Cho, A. Tropsha, Journal of Medicinal Chemistry 1995, 38, 1060.